Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $166.19 USD
Change Today -1.93 / -1.15%
Volume 1.2M
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Open
$167.22
Previous Close
$168.12
Day High
$168.05
Day Low
$164.77
52 Week High
12/3/14 - $203.30
52 Week Low
05/6/15 - $150.06
Market Cap
33.2B
Average Volume 10 Days
1.9M
EPS TTM
$3.12
Shares Outstanding
199.6M
EX-Date
--
P/E TM
53.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (ALXN)

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

2,273 Employees
Last Reported Date: 02/6/15
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $696.1K
Co-Founder, Chairman of The Board and Consult...
Total Annual Compensation: $1.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $715.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $650.0K
Chief Strategy & Portfolio Officer and Execut...
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals Announces Plans to Expand Its Operations in Ireland

Alexion Pharmaceuticals announced plans to expand its operations in Ireland by constructing the company's first ever biologics manufacturing facility outside the United States. The E450 million, four-year project, which will be constructed at Alexion's College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, which will bring Alexion's total workforce in Ireland to almost 500 employees. Furthermore, approximately 560 construction workers are involved in the development of the current Athlone and College Park projects, and the planned expansion of College Park will also create over 800 construction jobs.

Alexion Pharmaceuticals, Inc. to Appoint Dr. Felix Baker to its Board

Alexion Pharmaceuticals, Inc. and Synageva BioPharma Corp. announced that they have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. Dr. Felix Baker, a deeply experienced board member and leader in the biopharmaceutical industry, will join the Alexion Board of Directors when the transaction is completed.

Alexion Pharmaceuticals, Inc., Synageva BioPharma Corp. - M&A Call

To discuss the acquisition transaction between Alexion Pharmaceuticals, Inc. and Synageva BioPharma Corp

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $166.19 USD -1.93

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,528 INR -58.70
Sigma-Aldrich Corp $138.88 USD -0.30
Symrise AG €57.98 EUR -0.227
United Therapeutics Corp $181.85 USD -1.61
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 57.6x
Price/Sales 14.8x
Price/Book 9.5x
Price/Cash Flow 57.0x
TEV/Sales 13.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.